Compare · ABBV vs BCAX
ABBV vs BCAX
Side-by-side comparison of AbbVie Inc. (ABBV) and Bicara Therapeutics Inc. (BCAX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABBV and BCAX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABBV is the larger of the two at $401.47B, about 305.5x BCAX ($1.31B).
- Over the past year, ABBV is up 18.0% and BCAX is up 76.4% - BCAX leads by 58.4 points.
- ABBV has been more active in the news (10 items in the past 4 weeks vs 6 for BCAX).
- ABBV has more recent analyst coverage (25 ratings vs 15 for BCAX).
- Company
- AbbVie Inc.
- Bicara Therapeutics Inc.
- Price
- $223.01-1.80%
- $20.11+0.53%
- Market cap
- $401.47B
- $1.31B
- 1M return
- +10.05%
- -12.95%
- 1Y return
- +17.97%
- +76.36%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2012
- 2024
- News (4w)
- 10
- 6
- Recent ratings
- 25
- 15
AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Latest ABBV
- AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026
- AbbVie to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
- SEC Form SD filed by AbbVie Inc.
- AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia
- FDA Approval for DECNUPAZ issued to ABBVIE INC
- U.S. FDA Approves DECNUPAZTM (pivekimab sunirine-pvzy) for Treatment of Adult Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options
- SEC Form 144 filed by AbbVie Inc.
- AbbVie Announces Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Acute Hepatitis C Infection
- AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline
- Allergan Aesthetics Receives Positive CHMP Opinion for Boey® (TrenibotulinumtoxinE) for the Temporary Improvement of Moderate to Severe Glabellar Lines in Adults
Latest BCAX
- SEC Form 144 filed by Bicara Therapeutics Inc.
- Chief Financial Officer Hyep Ivan exercised 9,200 shares at a strike of $3.79 and sold $187,883 worth of shares (9,200 units at $20.42) as part of a pre-agreed trading plan (SEC Form 4)
- Bicara Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC
- Chief Executive Officer Mazumdar Claire exercised 15,000 shares at a strike of $3.79 and sold $300,579 worth of shares (15,000 units at $20.04) as part of a pre-agreed trading plan (SEC Form 4)
- President and COO Cohlhepp Ryan exercised 8,000 shares at a strike of $3.79 and sold $253,649 worth of shares (12,500 units at $20.29) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 191,641 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Bicara Therapeutics Inc.
- SEC Form SCHEDULE 13G filed by Bicara Therapeutics Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Bicara Therapeutics Inc.
- Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)